IRF6 and neoplasm: In a mouse model for pancreatic ductal adenocarcinoma, acquired resistance of tumor cells to immune checkpoint inhibition was shown to be mediated by decreased expression of IRF6, which results in an inability of tumor cells to be killed by TNF-α released from immune cells [39].